9:00am - 10:00am

KEYNOTE PRESENTATION

Salon A-F
Georgina Long

Session available virtually

10:00am - 10:30am
Refreshment Break

10:30am - 12:00pm

PLENARY SESSION 10 - Late Breaking Clinical Abstracts

Salon A-F
Session Chairs: Sapna Patel

10:30am - 10:45am

15 Mins

DREAMseq (EA6134): a Phase III Trial of treatment sequences in BRAFV600-mutant (m) metastatic melanoma (MM): Final 2-year OS Data and Biomarkers

Michael Atkins

10:45am - 11:00am

15 Mins

Lenvatinib plus pembrolizumab (len + pembro) versus pembro alone for unresectable or metastatic melanoma (MEL): results of LEAP-003

Ana Arance

11:00am - 11:15am

15 Mins

A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab+ ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label Phase 2 SCOPE trial

Fayaz Master

11:15am - 11:30am

15 Mins

A Phase I/II Study of DYP688, an Antibody Drug Conjugate Delivering a Direct Gq/11 Inhibitor in Patients With Metastatic Uveal Melanoma (MUM) and Other GNAQ/11 Mutant Melanomas

Matteo Carlino

11:30am - 11:45am

15 Mins

Combined inhibition of MEK1/2 plus Autophagy in Metastatic/Locally Advanced, Unresectable NRAS-Mutated Melanoma: A Phase Ib/II trial of trametinib plus hydroxychloroquine in patients with NRAS-Mutated Melanoma (CHLORO TRAM MEL, NCT03979651)

Amelie Boespflug